Search research articles
Contact Us
Filters
Showing results (31-40 of 61) with videos related to
Page
of 7
Sort By:
Contemporary Clinical Trials Communications
|
October 26, 2019
First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)
Toan Pham, Lloyd Pereira, Sara Roth, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 22, 2018
Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN)
Grace Kong, Simona Grozinsky-Glasberg, Michael S Hofman, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 13, 2019
The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma
Grace Kong, Tess Schenberg, Christopher J Yates, et al.
Annals of Surgery
|
August 10, 2002
Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer
Anthony Hannah, Andrew M Scott, Henri Tochon-Danguy, et al.
Internal Medicine Journal
|
December 6, 2018
The Victorian Comprehensive Cancer Centre lung cancer clinical audit: collecting the UK National Lung Cancer Audit data from hospitals in Australia
Linda Mileshkin, Catherine Dunn, Hannah Cross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2007
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus
Gregory J Riely, Mark G Kris, Binsheng Zhao, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 29, 2021
Efficacy and Safety of <sup>177</sup>Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
Lamiaa Zidan, Amir Iravani, Kira Oleinikov, et al.
European Urology Oncology
|
August 15, 2019
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for <sup>177</sup>Lu-labelled PSMA Radioligand Therapy
Sue Ping Thang, John Violet, Shahneen Sandhu, et al.
Endocrine Oncology (Bristol, England)
|
December 9, 2024
Peptide receptor radionuclide therapy for ectopic Cushing's syndrome caused by metastatic neuroendocrine neoplasms
Emma Boehm, Terry Hung, Tim Akhurst, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 6, 2026
First Images on a Next-Generation Extended-Field-of-View Digital Bismuth Germanium Oxide Total-Body PET/CT
Michael S Hofman, Alicia Corlett, Cameron Pain, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 61) with videos related to
Sort By:
Page
of 7
Contemporary Clinical Trials Communications
|
October 26, 2019
First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)
Toan Pham, Lloyd Pereira, Sara Roth, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 22, 2018
Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN)
Grace Kong, Simona Grozinsky-Glasberg, Michael S Hofman, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 13, 2019
The Role of 68Ga-DOTA-Octreotate PET/CT in Follow-Up of SDH-Associated Pheochromocytoma and Paraganglioma
Grace Kong, Tess Schenberg, Christopher J Yates, et al.
Annals of Surgery
|
August 10, 2002
Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer
Anthony Hannah, Andrew M Scott, Henri Tochon-Danguy, et al.
Internal Medicine Journal
|
December 6, 2018
The Victorian Comprehensive Cancer Centre lung cancer clinical audit: collecting the UK National Lung Cancer Audit data from hospitals in Australia
Linda Mileshkin, Catherine Dunn, Hannah Cross, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 6, 2007
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus
Gregory J Riely, Mark G Kris, Binsheng Zhao, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 29, 2021
Efficacy and Safety of <sup>177</sup>Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study
Lamiaa Zidan, Amir Iravani, Kira Oleinikov, et al.
European Urology Oncology
|
August 15, 2019
Poor Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer with Low Prostate-specific Membrane Antigen (PSMA) Expression Deemed Ineligible for <sup>177</sup>Lu-labelled PSMA Radioligand Therapy
Sue Ping Thang, John Violet, Shahneen Sandhu, et al.
Endocrine Oncology (Bristol, England)
|
December 9, 2024
Peptide receptor radionuclide therapy for ectopic Cushing's syndrome caused by metastatic neuroendocrine neoplasms
Emma Boehm, Terry Hung, Tim Akhurst, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 6, 2026
First Images on a Next-Generation Extended-Field-of-View Digital Bismuth Germanium Oxide Total-Body PET/CT
Michael S Hofman, Alicia Corlett, Cameron Pain, et al.
Page
of 7